A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Avelumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms JAVELIN Lung 100
- Sponsors EMD Serono; Merck KGaA
- 07 Jul 2017 Planned End Date changed from 30 Apr 2024 to 26 Jul 2024.
- 07 Jul 2017 Planned primary completion date changed from 30 Apr 2019 to 25 Jul 2019.
- 10 Jun 2017 Biomarkers information updated